Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

ALENDRONATE SODIUM

ALENDRONATE SODIUM

Standard Dose
EQ 5MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview ALENDRONATE SODIUM is listed in Drugs@FDA under application 090557 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ALENDRONATE SODIUM Form and strength TABLET;ORAL - EQ 5MG BASE Sponsor JUBILANT CADISTA Submission history Latest submission status date: 2022-10-14 00:00:00.

Structured Monograph

Clinical summary

Approval overview ALENDRONATE SODIUM is listed in Drugs@FDA under application 090557 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ALENDRONATE SODIUM Form and strength TABLET;ORAL - EQ 5MG BASE Sponsor JUBILANT CADISTA Submission history Latest submission status date: 2022-10-14 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.